1. ALLA AKTIER
  2. NYHETER
  3. CANTARGIA

Cantargia

Nyheter Cantargia Nyheter alla bolag

Invitation to the presentation of Cantargia’s H1 2025 report

Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) will publish the company’s interim report for the first six months of 2025 on Thursday, August 21, 2025, at 07:00 a.m. CEST.

In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on August 21, at 3:00 p.m. CEST, where Cantargia’s interim CEO Damian Marron, CBO Ton Berkien, and CFO Patrik Renblad, will present Cantargia and comment on the report, followed by a Q&A-session.

If you wish to participate via audiocast, please use the link below. Via the web session you will be able to ask written questions. Webcast: https://cantargia.events.inderes.com/q2-report-2025.

If you wish to participate via teleconference, please register on the link below. After registration you will be provided with phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://events.inderes.com/cantargia/q2-report-2025/dial-in.

The webcast will also be available on demand on Cantargia’s corporate website: www.cantargia.com.

For further information, please contact
Damian Marron, Interim CEO
Telephone: +46 (0)46-275 62 60
E-mail: damian.marron@cantargia.com

About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia’s oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases.
 
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.

Attachments
Invitation to the presentation of Cantargia’s H1 2025 report

Datum 2025-08-12, kl 10:15
Källa MFN
Bifogade filer
Invitation to the presentation of Cantargia’s H1 2025 report
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!